An open-label, exploratory clinical trial to investigate the effects of Ginkgo biloba special extract EGb 761 on dopamine-induced executive cognitive functions and their neurophysiological correlation in subjects with mild cognitive deficits.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EGb 761 (Primary)
Indications Mild cognitive impairment
Focus Pharmacodynamics
Sponsors Dr. Willmar Schwabe Group

Most Recent Events

01 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
14 Apr 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight